蒲元和胃胶囊联合莫沙必利和泮托拉唑治疗反流性食管炎的疗效观察

目的探讨蒲元和胃胶囊联合莫沙必利和泮托拉唑治疗反流性食管炎的临床疗效。方法选取安阳市人民医院2013年10月—2016年10月收治的102例反流性食管炎患者,随机分为对照组和治疗组,每组各51例。对照组患者饭前口服枸橼酸莫沙必利片,1片/次,3次/d;同时早晨空腹口服泮托拉唑钠肠溶片,1片/次,1次/d。治疗组患者在对照组的基础上于饭后1 h口服蒲元和胃胶囊,4粒/次,3次/d。两组患者均连续治疗6周。评价两组患者临床疗效,比较治疗前后两组患者生活质量和临床症状评分。结果治疗后,对照组的总有效率为84.31%,显著低于治疗组的96.08%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者各项生活质量评分均较治疗前明显升高,临床症状评分均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组患者生活质量和临床症状评分改善程度显著优于对照组,两组比较差异有统计学意义(P0.05)。结论蒲元和胃胶囊联合莫沙必利和泮托拉唑治疗反流性食管炎疗效显著,安全性较高,具有一定的临床推广应用价值。

Clinical observation of Puyuan Hewei Capsules combined with mosapride and pantoprazole in treatment of reflux esophagitis

Objective To evaluate the clinical efficacy of Puyuan Hewei Capsules combined with mosapride and pantoprazole in treatment of reflux esophagitis. Methods Patients (102 cases) with reflux esophagitis in the People''s Hospital of Anyang from October 2013 to October 2016 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Mosapride Citrate Tablets before meals, 1 tablet/time, three times daily. And they were fasting po administered with Pantoprazole sodium Enteric-Coated Tablets at the same time, 1 tablet/time, once daily. Patients in the treatment group were po administered with Puyuan Hewei Capsules on the basis of the control group 1 h after meals, 4 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the quality of life and clinical symptoms scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control was 84.31%, which was significantly lower than 96.08% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the quality of life score in two groups significantly increased, and clinical symptoms score significantly decreased, the difference was statistically significant in the same group (P < 0.05). And the quality of life and clinical symptoms scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Puyuan Hewei Capsules combined with mosapride and pantoprazole has significant clinical efficacy in treatment of reflux esophagitis with good safety, which has a certain clinical application value.